IGC Pharma (IGC) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $0.02.
- Pharma's Debt to Equity fell 1086.18% to $0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year decrease of 1086.18%. This contributed to the annual value of $0.02 for FY2025, which is 1312.3% up from last year.
- As of Q3 2025, Pharma's Debt to Equity stood at $0.02, which was down 1086.18% from $0.02 recorded in Q2 2025.
- Pharma's 5-year Debt to Equity high stood at $0.02 for Q2 2025, and its period low was $0.0 during Q2 2021.
- In the last 5 years, Pharma's Debt to Equity had a median value of $0.01 in 2023 and averaged $0.01.
- Examining YoY changes over the last 5 years, Pharma's Debt to Equity showed a top increase of 83841.78% in 2021 and a maximum decrease of 8141.12% in 2021.
- Over the past 5 years, Pharma's Debt to Equity (Quarter) stood at $0.01 in 2021, then soared by 53.31% to $0.01 in 2022, then soared by 98.03% to $0.02 in 2023, then skyrocketed by 40.45% to $0.02 in 2024, then decreased by 23.81% to $0.02 in 2025.
- Its Debt to Equity stands at $0.02 for Q3 2025, versus $0.02 for Q2 2025 and $0.02 for Q1 2025.